Table of Contents Author Guidelines Submit a Manuscript
Oxidative Medicine and Cellular Longevity
Volume 2017 (2017), Article ID 1378175, 14 pages
https://doi.org/10.1155/2017/1378175
Review Article

Collaborative Power of Nrf2 and PPARγ Activators against Metabolic and Drug-Induced Oxidative Injury

College of Pharmacy, Dongguk University, Goyang 10326, Republic of Korea

Correspondence should be addressed to Choongho Lee; moc.liamg@046jkl

Received 6 April 2017; Accepted 25 July 2017; Published 27 August 2017

Academic Editor: M. Yvonne Alexander

Copyright © 2017 Choongho Lee. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. M. Hayyan, M. A. Hashim, and I. M. AlNashef, “Superoxide ion: generation and chemical implications,” Chemical Reviews, vol. 116, no. 5, pp. 3029–3085, 2016. View at Publisher · View at Google Scholar · View at Scopus
  2. M. Kvandova, M. Majzunova, and I. Dovinova, “The role of PPARgamma in cardiovascular diseases,” Physiological Research, vol. 65, Supplementum 3, pp. S343–S363, 2016. View at Google Scholar
  3. H. R. Griffiths, “ROS as signalling molecules in T cells—evidence for abnormal redox signalling in the autoimmune disease, rheumatoid arthritis,” Redox Report, vol. 10, no. 6, pp. 273–280, 2005. View at Publisher · View at Google Scholar · View at Scopus
  4. B. D'Autreaux and M. B. Toledano, “ROS as signalling molecules: mechanisms that generate specificity in ROS homeostasis,” Nature Reviews Molecular Cell Biology, vol. 8, no. 10, pp. 813–824, 2007. View at Publisher · View at Google Scholar · View at Scopus
  5. J. Kim and Y. S. Keum, “NRF2, a key regulator of antioxidants with two faces towards cancer,” Oxidative Medicine and Cellular Longevity, vol. 2016, Article ID 2746457, 7 pages, 2016. View at Publisher · View at Google Scholar · View at Scopus
  6. F. L. Muller, M. S. Lustgarten, Y. Jang, A. Richardson, and H. Van Remmen, “Trends in oxidative aging theories,” Free Radical Biology & Medicine, vol. 43, no. 4, pp. 477–503, 2007. View at Publisher · View at Google Scholar · View at Scopus
  7. J. M. Van Raamsdonk and S. Hekimi, “Deletion of the mitochondrial superoxide dismutase sod-2 extends lifespan in Caenorhabditis elegans,” PLoS Genetics, vol. 5, no. 2, article e1000361, 2009. View at Publisher · View at Google Scholar · View at Scopus
  8. J. M. Carney, P. E. Starke-Reed, C. N. Oliver et al., “Reversal of age-related increase in brain protein oxidation, decrease in enzyme activity, and loss in temporal and spatial memory by chronic administration of the spin-trapping compound N-tert-butyl-alpha-phenylnitrone,” Proceedings of the National Academy of Sciences of the United States of America, vol. 88, no. 9, pp. 3633–3636, 1991. View at Google Scholar
  9. E. R. Stadtman, “Protein oxidation and aging,” Science, vol. 257, no. 5074, pp. 1220–1224, 1992. View at Google Scholar
  10. J. Liu, E. Head, A. M. Gharib et al., “Memory loss in old rats is associated with brain mitochondrial decay and RNA/DNA oxidation: partial reversal by feeding acetyl-L-carnitine and/or R-alpha-lipoic acid,” Proceedings of the National Academy of Sciences of the United States of America, vol. 99, no. 4, pp. 2356–2361, 2002. View at Publisher · View at Google Scholar · View at Scopus
  11. S. C. Gupta, D. Hevia, S. Patchva, B. Park, W. Koh, and B. B. Aggarwal, “Upsides and downsides of reactive oxygen species for cancer: the roles of reactive oxygen species in tumorigenesis, prevention, and therapy,” Antioxidants & Redox Signaling, vol. 16, no. 11, pp. 1295–1322, 2012. View at Publisher · View at Google Scholar · View at Scopus
  12. U. Forstermann, N. Xia, and H. Li, “Roles of vascular oxidative stress and nitric oxide in the pathogenesis of atherosclerosis,” Circulation Research, vol. 120, no. 4, pp. 713–735, 2017. View at Publisher · View at Google Scholar
  13. A. Konior, A. Schramm, M. Czesnikiewicz-Guzik, and T. J. Guzik, “NADPH oxidases in vascular pathology,” Antioxidants & Redox Signaling, vol. 20, no. 17, pp. 2794–2814, 2014. View at Publisher · View at Google Scholar · View at Scopus
  14. P. Newsholme, V. F. Cruzat, K. N. Keane, R. Carlessi, and P. I. d. Bittencourt Jr., “Molecular mechanisms of ROS production and oxidative stress in diabetes,” The Biochemical Journal, vol. 473, no. 24, pp. 4527–4550, 2016. View at Publisher · View at Google Scholar
  15. K. Kandola, A. Bowman, and M. A. Birch-Machin, “Oxidative stress—a key emerging impact factor in health, ageing, lifestyle and aesthetics,” International Journal of Cosmetic Science, vol. 37, Supplement 2, pp. 1–8, 2015. View at Publisher · View at Google Scholar · View at Scopus
  16. A. G. Miranda-Diaz, L. Pazarin-Villasenor, F. G. Yanowsky-Escatell, and J. Andrade-Sierra, “Oxidative stress in diabetic nephropathy with early chronic kidney disease,” Journal of Diabetes Research, vol. 2016, Article ID 7047238, 7 pages, 2016. View at Publisher · View at Google Scholar · View at Scopus
  17. J. X. Jiang and N. J. Torok, “NADPH oxidases in chronic liver diseases,” Advances in Hepatology, vol. 2014, Article ID 742931, 8 pages, 2014. View at Publisher · View at Google Scholar
  18. P. Moi, K. Chan, I. Asunis, A. Cao, and Y. W. Kan, “Isolation of NF-E2-related factor 2 (Nrf2), a NF-E2-like basic leucine zipper transcriptional activator that binds to the tandem NF-E2/AP1 repeat of the beta-globin locus control region,” Proceedings of the National Academy of Sciences of the United States of America, vol. 91, no. 21, pp. 9926–9930, 1994. View at Google Scholar
  19. M. Kobayashi, L. Li, N. Iwamoto et al., “The antioxidant defense system Keap1-Nrf2 comprises a multiple sensing mechanism for responding to a wide range of chemical compounds,” Molecular and Cellular Biology, vol. 29, no. 2, pp. 493–502, 2009. View at Publisher · View at Google Scholar · View at Scopus
  20. K. Itoh, N. Wakabayashi, Y. Katoh et al., “Keap1 represses nuclear activation of antioxidant responsive elements by Nrf2 through binding to the amino-terminal Neh2 domain,” Genes & Development, vol. 13, no. 1, pp. 76–86, 1999. View at Google Scholar
  21. A. Kobayashi, M. I. Kang, H. Okawa et al., “Oxidative stress sensor Keap1 functions as an adaptor for Cul3-based E3 ligase to regulate proteasomal degradation of Nrf2,” Molecular and Cellular Biology, vol. 24, no. 16, pp. 7130–7139, 2004. View at Publisher · View at Google Scholar · View at Scopus
  22. A. Kobayashi, M. I. Kang, Y. Watai et al., “Oxidative and electrophilic stresses activate Nrf2 through inhibition of ubiquitination activity of Keap1,” Molecular and Cellular Biology, vol. 26, no. 1, pp. 221–229, 2006. View at Publisher · View at Google Scholar · View at Scopus
  23. B. N. Das, Y. W. Kim, and Y. S. Keum, “Mechanisms of Nrf2/Keap1-dependent phase II cytoprotective and detoxifying gene expression and potential cellular targets of chemopreventive isothiocyanates,” Oxidative Medicine and Cellular Longevity, vol. 2013, Article ID 839409, 7 pages, 2013. View at Publisher · View at Google Scholar · View at Scopus
  24. H. Y. Cho, S. P. Reddy, A. Debiase, M. Yamamoto, and S. R. Kleeberger, “Gene expression profiling of NRF2-mediated protection against oxidative injury,” Free Radical Biology & Medicine, vol. 38, no. 3, pp. 325–343, 2005. View at Publisher · View at Google Scholar · View at Scopus
  25. W. A. Solis, T. P. Dalton, M. Z. Dieter et al., “Glutamate-cysteine ligase modifier subunit: mouse Gclm gene structure and regulation by agents that cause oxidative stress,” Biochemical Pharmacology, vol. 63, no. 9, pp. 1739–1754, 2002. View at Google Scholar
  26. R. Venugopal and A. K. Jaiswal, “Nrf1 and Nrf2 positively and c-Fos and Fra1 negatively regulate the human antioxidant response element-mediated expression of NAD(P)H:quinone oxidoreductase1 gene,” Proceedings of the National Academy of Sciences of the United States of America, vol. 93, no. 25, pp. 14960–14965, 1996. View at Google Scholar
  27. Y. H. Jeong, J. S. Park, D. H. Kim, and H. S. Kim, “Lonchocarpine increases Nrf2/ARE-mediated antioxidant enzyme expression by modulating AMPK and MAPK signaling in brain astrocytes,” Biomolecules & Therapeutics (Seoul), vol. 24, no. 6, pp. 581–588, 2016. View at Publisher · View at Google Scholar · View at Scopus
  28. C. H. Jin, Y. K. So, S. N. Han, and J. B. Kim, “Isoegomaketone upregulates heme oxygenase-1 in RAW264.7 cells via ROS/p38 MAPK/Nrf2 pathway,” Biomolecules & Therapeutics (Seoul), vol. 24, no. 5, pp. 510–516, 2016. View at Publisher · View at Google Scholar · View at Scopus
  29. W. Miao, L. Hu, P. J. Scrivens, and G. Batist, “Transcriptional regulation of NF-E2 p45-related factor (NRF2) expression by the aryl hydrocarbon receptor-xenobiotic response element signaling pathway: direct cross-talk between phase I and II drug-metabolizing enzymes,” The Journal of Biological Chemistry, vol. 280, no. 21, pp. 20340–20348, 2005. View at Publisher · View at Google Scholar · View at Scopus
  30. M. Yang, Y. Yao, G. Eades, Y. Zhang, and Q. Zhou, “MiR-28 regulates Nrf2 expression through a Keap1-independent mechanism,” Breast Cancer Research and Treatment, vol. 129, no. 3, pp. 983–991, 2011. View at Publisher · View at Google Scholar · View at Scopus
  31. G. Eades, M. Yang, Y. Yao, Y. Zhang, and Q. Zhou, “miR-200a regulates Nrf2 activation by targeting Keap1 mRNA in breast cancer cells,” The Journal of Biological Chemistry, vol. 286, no. 47, pp. 40725–40733, 2011. View at Publisher · View at Google Scholar · View at Scopus
  32. S. B. Cullinan and J. A. Diehl, “Coordination of ER and oxidative stress signaling: the PERK/Nrf2 signaling pathway,” The International Journal of Biochemistry & Cell Biology, vol. 38, no. 3, pp. 317–332, 2006. View at Publisher · View at Google Scholar · View at Scopus
  33. H. C. Huang, T. Nguyen, and C. B. Pickett, “Phosphorylation of Nrf2 at Ser-40 by protein kinase C regulates antioxidant response element-mediated transcription,” The Journal of Biological Chemistry, vol. 277, no. 45, pp. 42769–42774, 2002. View at Publisher · View at Google Scholar · View at Scopus
  34. Y. Katoh, K. Itoh, E. Yoshida, M. Miyagishi, A. Fukamizu, and M. Yamamoto, “Two domains of Nrf2 cooperatively bind CBP, a CREB binding protein, and synergistically activate transcription,” Genes to Cells, vol. 6, no. 10, pp. 857–868, 2001. View at Google Scholar
  35. Z. Sun, Y. E. Chin, and D. D. Zhang, “Acetylation of Nrf2 by p300/CBP augments promoter-specific DNA binding of Nrf2 during the antioxidant response,” Molecular and Cellular Biology, vol. 29, no. 10, pp. 2658–2672, 2009. View at Publisher · View at Google Scholar · View at Scopus
  36. C. M. Clements, R. S. McNally, B. J. Conti, T. W. Mak, and J. P. Ting, “DJ-1, a cancer- and Parkinson’s disease-associated protein, stabilizes the antioxidant transcriptional master regulator Nrf2,” Proceedings of the National Academy of Sciences of the United States of America, vol. 103, no. 41, pp. 15091–15096, 2006. View at Publisher · View at Google Scholar · View at Scopus
  37. Y. Zheng, A. Morris, M. Sunkara, J. Layne, M. Toborek, and B. Hennig, “Epigallocatechin-gallate stimulates NF-E2-related factor and heme oxygenase-1 via caveolin-1 displacement,” The Journal of Nutritional Biochemistry, vol. 23, no. 2, pp. 163–168, 2012. View at Publisher · View at Google Scholar · View at Scopus
  38. W. Chen, Z. Sun, X. J. Wang et al., “Direct interaction between Nrf2 and p21(Cip1/WAF1) upregulates the Nrf2-mediated antioxidant response,” Molecular Cell, vol. 34, no. 6, pp. 663–673, 2009. View at Publisher · View at Google Scholar · View at Scopus
  39. J. D. Hayes and A. T. Dinkova-Kostova, “The Nrf2 regulatory network provides an interface between redox and intermediary metabolism,” Trends in Biochemical Sciences, vol. 39, no. 4, pp. 199–218, 2014. View at Publisher · View at Google Scholar · View at Scopus
  40. J. N. Feige, L. Gelman, L. Michalik, B. Desvergne, and W. Wahli, “From molecular action to physiological outputs: peroxisome proliferator-activated receptors are nuclear receptors at the crossroads of key cellular functions,” Progress in Lipid Research, vol. 45, no. 2, pp. 120–159, 2006. View at Publisher · View at Google Scholar · View at Scopus
  41. J. Berger and D. E. Moller, “The mechanisms of action of PPARs,” Annual Review of Medicine, vol. 53, pp. 409–435, 2002. View at Publisher · View at Google Scholar · View at Scopus
  42. A. Belfiore, M. Genua, and R. Malaguarnera, “PPAR-gamma agonists and their effects on IGF-I receptor signaling: implications for cancer,” PPAR Research, vol. 2009, Article ID 830501, 18 pages, 2009. View at Publisher · View at Google Scholar · View at Scopus
  43. K. R. Dunning, M. R. Anastasi, V. J. Zhang, D. L. Russell, and R. L. Robker, “Regulation of fatty acid oxidation in mouse cumulus-oocyte complexes during maturation and modulation by PPAR agonists,” PLoS One, vol. 9, no. 2, article e87327, 2014. View at Publisher · View at Google Scholar · View at Scopus
  44. I. Rusyn, M. L. Rose, H. K. Bojes, and R. G. Thurman, “Novel role of oxidants in the molecular mechanism of action of peroxisome proliferators,” Antioxidants & Redox Signaling, vol. 2, no. 3, pp. 607–621, 2000. View at Publisher · View at Google Scholar
  45. T. Varga, Z. Czimmerer, and L. Nagy, “PPARs are a unique set of fatty acid regulated transcription factors controlling both lipid metabolism and inflammation,” Biochimica et Biophysica Acta, vol. 1812, no. 8, pp. 1007–1022, 2011. View at Publisher · View at Google Scholar · View at Scopus
  46. A. Y. Swati Agarwal and R. K. Chaturvedi, “Peroxisome proliferator-activated receptors (PPARs) as therapeutic target in neurodegenerative disorders,” Biochemical and Biophysical Research Communications, vol. 483, no. 4, pp. 1166–1177, 2017. View at Publisher · View at Google Scholar · View at Scopus
  47. B. Desvergne and W. Wahli, “Peroxisome proliferator-activated receptors: nuclear control of metabolism,” Endocrine Reviews, vol. 20, no. 5, pp. 649–688, 1999. View at Publisher · View at Google Scholar
  48. S. Polvani, M. Tarocchi, and A. Galli, “PPARgamma and oxidative stress: con(beta) catenating NRF2 and FOXO,” PPAR Research, vol. 2012, Article ID 641087, 15 pages, 2012. View at Publisher · View at Google Scholar · View at Scopus
  49. G. Kronke, A. Kadl, E. Ikonomu et al., “Expression of heme oxygenase-1 in human vascular cells is regulated by peroxisome proliferator-activated receptors,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 27, no. 6, pp. 1276–1282, 2007. View at Publisher · View at Google Scholar · View at Scopus
  50. X. Wang, Z. Wang, J. Z. Liu et al., “Double antioxidant activities of rosiglitazone against high glucose-induced oxidative stress in hepatocyte,” Toxicology in Vitro, vol. 25, no. 4, pp. 839–847, 2011. View at Publisher · View at Google Scholar · View at Scopus
  51. E. D. Rosen and B. M. Spiegelman, “PPARgamma: a nuclear regulator of metabolism, differentiation, and cell growth,” The Journal of Biological Chemistry, vol. 276, no. 41, pp. 37731–37734, 2001. View at Publisher · View at Google Scholar
  52. J. R. Jones, C. Barrick, K. A. Kim et al., “Deletion of PPARgamma in adipose tissues of mice protects against high fat diet-induced obesity and insulin resistance,” Proceedings of the National Academy of Sciences of the United States of America, vol. 102, no. 17, pp. 6207–6212, 2005. View at Publisher · View at Google Scholar · View at Scopus
  53. D. B. Savage, “PPAR gamma as a metabolic regulator: insights from genomics and pharmacology,” Expert Reviews in Molecular Medicine, vol. 7, no. 1, pp. 1–16, 2005. View at Publisher · View at Google Scholar · View at Scopus
  54. S. M. Rangwala and M. A. Lazar, “Peroxisome proliferator-activated receptor gamma in diabetes and metabolism,” Trends in Pharmacological Sciences, vol. 25, no. 6, pp. 331–336, 2004. View at Publisher · View at Google Scholar · View at Scopus
  55. H. P. Koeffler, “Peroxisome proliferator-activated receptor gamma and cancers,” Clinical Cancer Research, vol. 9, no. 1, pp. 1–9, 2003. View at Google Scholar
  56. Y. Li, Y. Qi, T. H. Huang, J. Yamahara, and B. D. Roufogalis, “Pomegranate flower: a unique traditional antidiabetic medicine with dual PPAR-alpha/-gamma activator properties,” Diabetes, Obesity & Metabolism, vol. 10, no. 1, pp. 10–17, 2008. View at Publisher · View at Google Scholar · View at Scopus
  57. H. Takano and I. Komuro, “Roles of peroxisome proliferator-activated receptor gamma in cardiovascular disease,” Journal of Diabetes and Its Complications, vol. 16, no. 1, pp. 108–114, 2002. View at Google Scholar
  58. Q. Shen, C. Chitchumroonchokchai, J. L. Thomas et al., “Adipocyte reporter assays: application for identification of anti-inflammatory and antioxidant properties of mangosteen xanthones,” Molecular Nutrition & Food Research, vol. 58, no. 2, pp. 239–247, 2014. View at Publisher · View at Google Scholar · View at Scopus
  59. L. Dubuquoy, C. Rousseaux, X. Thuru et al., “PPARgamma as a new therapeutic target in inflammatory bowel diseases,” Gut, vol. 55, no. 9, pp. 1341–1349, 2006. View at Publisher · View at Google Scholar · View at Scopus
  60. B. Vandewalle, E. Moerman, B. Lefebvre et al., “PPARgamma-dependent and -independent effects of rosiglitazone on lipotoxic human pancreatic islets,” Biochemical and Biophysical Research Communications, vol. 366, no. 4, pp. 1096–1101, 2008. View at Publisher · View at Google Scholar · View at Scopus
  61. R. C. Reddy and T. J. Standiford, “Nrf2 and PPAR{gamma}: PPARtnering against oxidant-induced lung injury,” American Journal of Respiratory and Critical Care Medicine, vol. 182, no. 2, pp. 134-135, 2010. View at Publisher · View at Google Scholar · View at Scopus
  62. X. Zhao, Y. Zhang, R. Strong, J. C. Grotta, and J. Aronowski, “15d-Prostaglandin J2 activates peroxisome proliferator-activated receptor-gamma, promotes expression of catalase, and reduces inflammation, behavioral dysfunction, and neuronal loss after intracerebral hemorrhage in rats,” Journal of Cerebral Blood Flow and Metabolism, vol. 26, no. 6, pp. 811–820, 2006. View at Publisher · View at Google Scholar · View at Scopus
  63. G. Ding, M. Fu, Q. Qin et al., “Cardiac peroxisome proliferator-activated receptor gamma is essential in protecting cardiomyocytes from oxidative damage,” Cardiovascular Research, vol. 76, no. 2, pp. 269–279, 2007. View at Publisher · View at Google Scholar · View at Scopus
  64. J. Huang, I. Tabbi-Anneni, V. Gunda, and L. Wang, “Transcription factor Nrf2 regulates SHP and lipogenic gene expression in hepatic lipid metabolism,” American Journal of Physiology - Gastrointestinal and Liver Physiology, vol. 299, no. 6, pp. G1211–G1221, 2010. View at Publisher · View at Google Scholar · View at Scopus
  65. H. Y. Cho, W. Gladwell, X. Wang et al., “Nrf2-regulated PPAR{gamma} expression is critical to protection against acute lung injury in mice,” American Journal of Respiratory and Critical Care Medicine, vol. 182, no. 2, pp. 170–182, 2010. View at Publisher · View at Google Scholar · View at Scopus
  66. B. N. Chorley, M. R. Campbell, X. Wang et al., “Identification of novel NRF2-regulated genes by ChIP-Seq: influence on retinoid X receptor alpha,” Nucleic Acids Research, vol. 40, no. 15, pp. 7416–7429, 2012. View at Publisher · View at Google Scholar · View at Scopus
  67. Y. Y. Wang, Y. X. Yang, H. Zhe, Z. X. He, and S. F. Zhou, “Bardoxolone methyl (CDDO-Me) as a therapeutic agent: an update on its pharmacokinetic and pharmacodynamic properties,” Drug Design, Development and Therapy, vol. 8, pp. 2075–2088, 2014. View at Publisher · View at Google Scholar · View at Scopus
  68. B. L. Probst, I. Trevino, L. McCauley et al., “RTA 408, a novel synthetic triterpenoid with broad anticancer and anti-inflammatory activity,” PLoS One, vol. 10, no. 4, article e0122942, 2015. View at Publisher · View at Google Scholar · View at Scopus
  69. Q. Q. Wu, Y. Wang, M. Senitko et al., “Bardoxolone methyl (BARD) ameliorates ischemic AKI and increases expression of protective genes Nrf2, PPARgamma, and HO-1,” American Journal of Physiology - Renal Physiology, vol. 300, no. 5, pp. F1180–F1192, 2011. View at Publisher · View at Google Scholar · View at Scopus
  70. D. de Zeeuw, T. Akizawa, P. Audhya et al., “Bardoxolone methyl in type 2 diabetes and stage 4 chronic kidney disease,” The New England Journal of Medicine, vol. 369, no. 26, pp. 2492–2503, 2013. View at Publisher · View at Google Scholar · View at Scopus
  71. A. S. Jimenez-Osorio, S. Gonzalez-Reyes, and J. Pedraza-Chaverri, “Natural Nrf2 activators in diabetes,” Clinica Chimica Acta, vol. 448, pp. 182–192, 2015. View at Publisher · View at Google Scholar · View at Scopus
  72. D. Olagnier, R. A. Lavergne, E. Meunier et al., “Nrf2, a PPARgamma alternative pathway to promote CD36 expression on inflammatory macrophages: implication for malaria,” PLoS Pathogens, vol. 7, no. 9, article e1002254, 2011. View at Publisher · View at Google Scholar · View at Scopus
  73. P. N. Mimche, E. Thompson, D. Taramelli, and L. Vivas, “Curcumin enhances non-opsonic phagocytosis of Plasmodium falciparum through up-regulation of CD36 surface expression on monocytes/macrophages,” The Journal of Antimicrobial Chemotherapy, vol. 67, no. 8, pp. 1895–1904, 2012. View at Publisher · View at Google Scholar · View at Scopus
  74. E. H. Kim and Y. J. Surh, “15-Deoxy-delta12,14-prostaglandin J2 as a potential endogenous regulator of redox-sensitive transcription factors,” Biochemical Pharmacology, vol. 72, no. 11, pp. 1516–1528, 2006. View at Publisher · View at Google Scholar · View at Scopus
  75. R. E. Haskew-Layton, J. B. Payappilly, H. Xu, S. A. Bennett, and R. R. Ratan, “15-Deoxy-delta12,14-prostaglandin J2 (15d-PGJ2) protects neurons from oxidative death via an Nrf2 astrocyte-specific mechanism independent of PPARgamma,” Journal of Neurochemistry, vol. 124, no. 4, pp. 536–547, 2013. View at Publisher · View at Google Scholar · View at Scopus
  76. P. Gong, D. Stewart, B. Hu et al., “Activation of the mouse heme oxygenase-1 gene by 15-deoxy-delta(12,14)-prostaglandin J(2) is mediated by the stress response elements and transcription factor Nrf2,” Antioxidants & Redox Signaling, vol. 4, no. 2, pp. 249–257, 2002. View at Publisher · View at Google Scholar · View at Scopus
  77. M. J. Gorczynski, P. K. Smitherman, T. E. Akiyama et al., “Activation of peroxisome proliferator-activated receptor gamma (PPARgamma) by nitroalkene fatty acids: importance of nitration position and degree of unsaturation,” Journal of Medicinal Chemistry, vol. 52, no. 15, pp. 4631–4639, 2009. View at Publisher · View at Google Scholar · View at Scopus
  78. D. J. Bates, P. K. Smitherman, A. J. Townsend, S. B. King, and C. S. Morrow, “Nitroalkene fatty acids mediate activation of Nrf2/ARE-dependent and PPARgamma-dependent transcription by distinct signaling pathways and with significantly different potencies,” Biochemistry, vol. 50, no. 36, pp. 7765–7773, 2011. View at Publisher · View at Google Scholar · View at Scopus
  79. A. Trostchansky and H. Rubbo, “Nitrated fatty acids: mechanisms of formation, chemical characterization, and biological properties,” Free Radical Biology & Medicine, vol. 44, no. 11, pp. 1887–1896, 2008. View at Publisher · View at Google Scholar · View at Scopus
  80. A. T. Reddy, S. P. Lakshmi, and R. C. Reddy, “The nitrated fatty acid 10-nitro-oleate diminishes severity of LPS-induced acute lung injury in mice,” PPAR Research, vol. 2012, Article ID 617063, 12 pages, 2012. View at Publisher · View at Google Scholar · View at Scopus
  81. J. Ohsumi, S. Sakakibara, J. Yamaguchi et al., “Troglitazone prevents the inhibitory effects of inflammatory cytokines on insulin-induced adipocyte differentiation in 3T3-L1 cells,” Endocrinology, vol. 135, no. 5, pp. 2279–2282, 1994. View at Publisher · View at Google Scholar · View at Scopus
  82. L. A. Faine, M. Rudnicki, F. A. Cesar et al., “Anti-inflammatory and antioxidant properties of a new arylidene-thiazolidinedione in macrophages,” Current Medicinal Chemistry, vol. 18, no. 22, pp. 3351–3360, 2011. View at Google Scholar
  83. Z. N. Liu, M. Zhao, Q. Zheng, H. Y. Zhao, W. J. Hou, and S. L. Bai, “Inhibitory effects of rosiglitazone on paraquat-induced acute lung injury in rats,” Acta Pharmacologica Sinica, vol. 34, no. 10, pp. 1317–1324, 2013. View at Publisher · View at Google Scholar · View at Scopus
  84. P. H. Shih, S. L. Hwang, C. T. Yeh, and G. C. Yen, “Synergistic effect of cyanidin and PPAR agonist against nonalcoholic steatohepatitis-mediated oxidative stress-induced cytotoxicity through MAPK and Nrf2 transduction pathways,” Journal of Agricultural and Food Chemistry, vol. 60, no. 11, pp. 2924–2933, 2012. View at Publisher · View at Google Scholar · View at Scopus
  85. X. Zhang, W. E. Zhao, L. Hu, L. Zhao, and J. Huang, “Carotenoids inhibit proliferation and regulate expression of peroxisome proliferators-activated receptor gamma (PPARgamma) in K562 cancer cells,” Archives of Biochemistry and Biophysics, vol. 512, no. 1, pp. 96–106, 2011. View at Publisher · View at Google Scholar · View at Scopus
  86. P. J. Beisswenger, “Methylglyoxal in diabetes: link to treatment, glycaemic control and biomarkers of complications,” Biochemical Society Transactions, vol. 42, no. 2, pp. 450–456, 2014. View at Publisher · View at Google Scholar · View at Scopus
  87. W. H. Hsu, B. H. Lee, Y. Y. Chang, Y. W. Hsu, and T. M. Pan, “A novel natural Nrf2 activator with PPARgamma-agonist (monascin) attenuates the toxicity of methylglyoxal and hyperglycemia,” Toxicology and Applied Pharmacology, vol. 272, no. 3, pp. 842–851, 2013. View at Publisher · View at Google Scholar · View at Scopus
  88. W. H. Hsu, B. H. Lee, C. H. Li, Y. W. Hsu, and T. M. Pan, “Monascin and AITC attenuate methylglyoxal-induced PPARgamma phosphorylation and degradation through inhibition of the oxidative stress/PKC pathway depending on Nrf2 activation,” Journal of Agricultural and Food Chemistry, vol. 61, no. 25, pp. 5996–6006, 2013. View at Publisher · View at Google Scholar · View at Scopus
  89. W. H. Hsu and T. M. Pan, “Treatment of metabolic syndrome with ankaflavin, a secondary metabolite isolated from the edible fungus Monascus spp,” Applied Microbiology and Biotechnology, vol. 98, no. 11, pp. 4853–4863, 2014. View at Publisher · View at Google Scholar · View at Scopus
  90. B. H. Lee, W. H. Hsu, Y. Y. Chang, H. F. Kuo, Y. W. Hsu, and T. M. Pan, “Ankaflavin: a natural novel PPARgamma agonist upregulates Nrf2 to attenuate methylglyoxal-induced diabetes in vivo,” Free Radical Biology & Medicine, vol. 53, no. 11, pp. 2008–2016, 2012. View at Publisher · View at Google Scholar · View at Scopus
  91. J. T. Kim, S. Barua, H. Kim et al., “Absorption study of genistein using solid lipid microparticles and nanoparticles: control of oral bioavailability by particle sizes,” Biomolecules & Therapeutics (Seoul), vol. 25, no. 4, pp. 452–459, 2017. View at Publisher · View at Google Scholar
  92. T. Zhang, F. Wang, H. X. Xu et al., “Activation of nuclear factor erythroid 2-related factor 2 and PPARgamma plays a role in the genistein-mediated attenuation of oxidative stress-induced endothelial cell injury,” The British Journal of Nutrition, vol. 109, no. 2, pp. 223–235, 2013. View at Publisher · View at Google Scholar · View at Scopus
  93. M. G. Traber and J. Atkinson, “Vitamin E, antioxidant and nothing more,” Free Radical Biology & Medicine, vol. 43, no. 1, pp. 4–15, 2007. View at Publisher · View at Google Scholar · View at Scopus
  94. P. Bozaykut, B. Karademir, B. Yazgan et al., “Effects of vitamin E on peroxisome proliferator-activated receptor gamma and nuclear factor-erythroid 2-related factor 2 in hypercholesterolemia-induced atherosclerosis,” Free Radical Biology & Medicine, vol. 70, pp. 174–181, 2014. View at Publisher · View at Google Scholar · View at Scopus
  95. V. Karuppagounder, S. Arumugam, R. A. Thandavarayan et al., “Naringenin ameliorates daunorubicin induced nephrotoxicity by mitigating AT1R, ERK1/2-NFkappaB p65 mediated inflammation,” International Immunopharmacology, vol. 28, no. 1, pp. 154–159, 2015. View at Publisher · View at Google Scholar · View at Scopus
  96. V. K. Gounder, S. Arumugam, W. Arozal et al., “Olmesartan protects against oxidative stress possibly through the Nrf2 signaling pathway and inhibits inflammation in daunorubicin-induced nephrotoxicity in rats,” International Immunopharmacology, vol. 18, no. 2, pp. 282–289, 2014. View at Publisher · View at Google Scholar · View at Scopus
  97. A. C. Le Lamer, H. Authier, I. Rouaud et al., “Protolichesterinic acid derivatives: alpha-methylene-gamma-lactones as potent dual activators of PPARgamma and Nrf2 transcriptional factors,” Bioorganic & Medicinal Chemistry Letters, vol. 24, no. 16, pp. 3819–3822, 2014. View at Publisher · View at Google Scholar · View at Scopus
  98. N. Scheinfeld, “Three cases of toxic skin eruptions associated with methotrexate and a compilation of methotrexate-induced skin eruptions,” Dermatology Online Journal, vol. 12, no. 7, p. 15, 2006. View at Google Scholar
  99. D. H. Solomon, J. M. Kremer, M. Fisher et al., “Comparative cancer risk associated with methotrexate, other non-biologic and biologic disease-modifying anti-rheumatic drugs,” Seminars in Arthritis and Rheumatism, vol. 43, no. 4, pp. 489–497, 2014. View at Publisher · View at Google Scholar · View at Scopus
  100. S. M. Abd El-Twab, W. G. Hozayen, O. E. Hussein, and A. M. Mahmoud, “18beta-Glycyrrhetinic acid protects against methotrexate-induced kidney injury by up-regulating the Nrf2/ARE/HO-1 pathway and endogenous antioxidants,” Renal Failure, vol. 38, no. 9, pp. 1516–1527, 2016. View at Publisher · View at Google Scholar · View at Scopus
  101. T. M. Motawi, N. A. Sadik, and A. Refaat, “Cytoprotective effects of DL-alpha-lipoic acid or squalene on cyclophosphamide-induced oxidative injury: an experimental study on rat myocardium, testicles and urinary bladder,” Food and Chemical Toxicology, vol. 48, no. 8-9, pp. 2326–2336, 2010. View at Publisher · View at Google Scholar · View at Scopus
  102. A. M. Mahmoud and H. S. Al Dera, “18beta-Glycyrrhetinic acid exerts protective effects against cyclophosphamide-induced hepatotoxicity: potential role of PPARgamma and Nrf2 upregulation,” Genes & Nutrition, vol. 10, no. 6, p. 41, 2015. View at Publisher · View at Google Scholar · View at Scopus
  103. T. Ye, J. Zhen, Y. Du et al., “Green tea polyphenol (-)-epigallocatechin-3-gallate restores Nrf2 activity and ameliorates crescentic glomerulonephritis,” PLoS One, vol. 10, no. 3, article e0119543, 2015. View at Publisher · View at Google Scholar · View at Scopus
  104. M. Mahmoud-Awny, A. S. Attia, M. F. Abd-Ellah, and H. S. El-Abhar, “Mangiferin mitigates gastric ulcer in ischemia/reperfused rats: involvement of PPAR-gamma, NF-kappaB and Nrf2/HO-1 signaling pathways,” PLoS One, vol. 10, no. 7, article e0132497, 2015. View at Publisher · View at Google Scholar · View at Scopus
  105. Y. Katsuyama, T. Tsuboi, N. Taira, M. Yoshioka, and H. Masaki, “3-O-Laurylglyceryl ascorbate activates the intracellular antioxidant system through the contribution of PPAR-gamma and Nrf2,” Journal of Dermatological Science, vol. 82, no. 3, pp. 189–196, 2016. View at Publisher · View at Google Scholar · View at Scopus
  106. A. M. Mahmoud, M. O. Germoush, M. F. Alotaibi, and O. E. Hussein, “Possible involvement of Nrf2 and PPARgamma up-regulation in the protective effect of umbelliferone against cyclophosphamide-induced hepatotoxicity,” Biomedicine & Pharmacotherapy, vol. 86, pp. 297–306, 2017. View at Publisher · View at Google Scholar
  107. A. Negre-Salvayre, R. Salvayre, N. Auge, R. Pamplona, and M. Portero-Otin, “Hyperglycemia and glycation in diabetic complications,” Antioxidants & Redox Signaling, vol. 11, no. 12, pp. 3071–3109, 2009. View at Publisher · View at Google Scholar · View at Scopus
  108. S. Schiekofer, M. Andrassy, J. Chen et al., “Acute hyperglycemia causes intracellular formation of CML and activation of ras, p42/44 MAPK, and nuclear factor kappaB in PBMCs,” Diabetes, vol. 52, no. 3, pp. 621–633, 2003. View at Google Scholar
  109. B. H. Lee, C. C. Lee, Y. H. Cheng, W. C. Chang, W. H. Hsu, and S. C. Wu, “Graptopetalum paraguayense and resveratrol ameliorates carboxymethyllysine (CML)-induced pancreas dysfunction and hyperglycemia,” Food and Chemical Toxicology, vol. 62, pp. 492–498, 2013. View at Publisher · View at Google Scholar · View at Scopus
  110. D. Serra, L. M. Almeida, and T. C. Dinis, “Anti-inflammatory protection afforded by cyanidin-3-glucoside and resveratrol in human intestinal cells via Nrf2 and PPAR-gamma: comparison with 5-aminosalicylic acid,” Chemico-Biological Interactions, vol. 260, pp. 102–109, 2016. View at Publisher · View at Google Scholar · View at Scopus